About the Authors

Surabhi S. Liyanage

surabhi_liyanage@hotmail.com

Affiliation School of Public Health and Community Medicine, UNSW Medicine, University of New South Wales, Sydney, Australia

Bayzidur Rahman

Affiliation School of Public Health and Community Medicine, UNSW Medicine, University of New South Wales, Sydney, Australia

Iman Ridda

Affiliation School of Public Health and Community Medicine, UNSW Medicine, University of New South Wales, Sydney, Australia

Anthony T. Newall

Affiliation School of Public Health and Community Medicine, UNSW Medicine, University of New South Wales, Sydney, Australia

Sepehr N. Tabrizi

Affiliation Department of Microbiology and Infectious Diseases, The Royal Women’s Hospital, Melbourne, Australia

Suzanne M. Garland

Affiliation Department of Microbiology and Infectious Diseases, The Royal Women’s Hospital, Melbourne, Australia

Eva Segelov

Affiliation Department of Medicine, St. Vincent’s Hospital Clinical School, University of New South Wales, Sydney, Australia

Holly Seale

Affiliation School of Public Health and Community Medicine, UNSW Medicine, University of New South Wales, Sydney, Australia

Philip J. Crowe

Affiliation Department of Surgery, Prince of Wales Hospital Clinical School, University of New South Wales, Sydney, Australia

Aye Moa

Affiliation School of Public Health and Community Medicine, UNSW Medicine, University of New South Wales, Sydney, Australia

C. Raina MacIntyre

Affiliation School of Public Health and Community Medicine, UNSW Medicine, University of New South Wales, Sydney, Australia

Competing Interests

ATN holds an NHMRC Training Fellowship (630724 - Australian Based Public Health Fellowship) and has previously received research funding for other projects from a manufacturer of HPV vaccine. HS currently holds a National Health and Medical Research Council (NHMRC) Training Fellowship (1012631) - Australian Based Public Health Fellowship). SG has received advisory board fees and grants support from CSL and GlaxoSmithKline, and lecture fees from Merck, GSK and Sanofi Pasteur; in addition, she has also received funding through her institution to conduct HPV vaccine studies for MSD and GSK. She is a member of the Merck Global Advisory Board as well as the Merck Scientific Advisory Committee for HPV. CRM has been on advisory boards for Merck, GSK and Pfizer for vaccines other than HPV. She has received funding for investigator-driven research on HPV vaccine from Merck. She has received funding for investigator driven research for other vaccines from GSK, CSL Biotherapies and Pfizer. The other authors have no competing interests to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: CRM BR ATN SL. Performed the experiments: BR SL. Analyzed the data: BR SL. Contributed reagents/materials/analysis tools: SL BR IR ATN SNT. Wrote the paper: SL CRM BR ATN ST SMG HS. Critical review and comments: BR IR ATN SNT SMG ES HS PJC AM CRM. Design of consrt diagram: AM. Editing of manuscript: AM SL.